JNJ stock: buy or sell?
November 15th, 2019
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide.
Should I buy JNJ stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Check the only buy setup that matches with Johnson & Johnson stock now:
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||Yes|
|100d MA crossing up 200d MA||No|
Is Johnson & Johnson stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 14 ratings published for JNJ stock in the last month. The general sentiment of these ratings is bullish for JNJ stock, with 11 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-27||Morgan Stanley||n/a||Equal Weight|
|2019-8-27||Goldman Sachs Group||n/a||Buy|
|2019-8-27||Credit Suisse Group||n/a||Buy|
|2019-7-18||Credit Suisse Group||n/a||Buy|
|2019-7-16||Royal Bank of Canada||n/a||Buy|
|2019-7-16||Bank of America||n/a||Hold|
|2019-7-12||Credit Suisse Group||n/a||Outperform|
|2019-5-6||Wells Fargo & Co||n/a||Outperform|
|2019-5-28||Goldman Sachs Group||n/a||Buy|
|2019-5-16||Credit Suisse Group||n/a||Outperform|
|2019-4-17||Morgan Stanley||Equal Weight||Equal Weight|
|2019-4-17||Credit Suisse Group||Outperform||Outperform|
JNJ stock analysis
Johnson & Johnson broke up the simple moving average line of 200 days today and closed at $134.94, soared a 3.04%.
Johnson & Johnson broke up the SMA line of 200d today and closed at $134.94, soared a 3.04%.
Johnson & Johnson crossed up the simple moving average line of 200d, closing at $134.94. Counting this, it's been 4 climbing weeks in a row, soaring a 5.51%.
Far behind is the all-time high Johnson & Johnson hit early December but price is just -7.52% below that top.
JNJ stock price history
JNJ IPO was on August 18th, 1980 at $0.01 per share1. Since then, JNJ stock surged a 1,349,300.00%, with a yearly average of 34,597.40%. If you had invested right after JNJ's IPO a $1,000 in JNJ stock in 1980, it would worth $13,493,000.00 today.
1: Adjusted price after possible price splits or reverse-splits.
JNJ stock historical price chart
JNJ stock reached all-time highs on December with a price of $145.91.
JNJ stock price target is $152.90Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' JNJ stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 12 price targets for JNJ stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-27||Goldman Sachs Group||Set Price Target||n/a||$169.00||-|
|2019-8-27||Credit Suisse Group||Set Price Target||n/a||$156.00||-|
|2019-7-18||Credit Suisse Group||Set Price Target||n/a||$156.00||-|
|2019-7-17||Raymond James||Lowers Target||$147.00||$146.00||-0.7%|
|2019-7-16||Bank of America||Reiterates||n/a||$150.00||-|
|2019-7-12||Credit Suisse Group||Initiates||n/a||$156.00||-|
|2019-5-6||Wells Fargo & Co||Reiterates||$152.00||$157.00||3.3%|
|2019-5-16||Credit Suisse Group||Raises Target||$152.00||$156.00||2.6%|
|2019-4-17||Raymond James||Raises Target||$145.00||$147.00||1.4%|
|2019-4-17||Morgan Stanley||Raises Target||$134.00||$145.00||8.2%|
|2019-4-17||Credit Suisse Group||Raises Target||$151.00||$152.00||0.7%|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince last April, when Johnson & Johnson presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Johnson & Johnson annual sales jumped a very good 6.71% to $81,581.00 million dollars from $76,450.00 marked in 2017. Instead, its income margin (compared to sales) climbed to 18.75%, that is $15,297.00 million. Johnson & Johnson fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Johnson & Johnson TTM sales up to March 2019 were $81,593.00 and earnings $14,679.00 M USD. When comparing this TTM figures with the last reported annuality, we can esteem Johnson & Johnson business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, stayed steady a tight 0.01%. Likewise, profit margin (net income/revenues) remained stable at 18.75%.
|2013||$71,260 M||-||$13,830 M19.4%||-|
|2014||$74,331 M||4.31%||$16,323 M22.0%||18.03%|
|2015||$70,074 M||-5.73%||$15,409 M22.0%||-5.60%|
|2016||$71,890 M||2.59%||$16,540 M23.0%||7.34%|
|2017||$76,450 M||6.34%||$1,300 M1.7%||-92.14%|
|2018||$81,581 M||6.71%||$15,297 M18.8%||1,076.69%|
|TTM||$81,593 M||0.01%||$14,679 M18.0%||-4.04%|
Quarterly financial resultsJohnson & Johnson posted $20,021.00 million in revenues for 2019-Q1, a -1.83% less compared to previous quarter. Reported quarter income marked $3,749.00 million with a profit margin of 18.73%. Profit margin raised a 3.81% compared to previous quarter when profit margin was 14.92%. When comparing turnover to same quarter last year, Johnson & Johnson sales marked a neutral movement and remained constant a 0.06%.
|2017-Q2||$18,850 M||-||$3,830 M20.3%||-|
|2017-Q3||$19,650 M||4.24%||$3,760 M19.1%||-1.83%|
|2017-Q4||$20,195 M||2.77%||$-10,713 M-53.0%||-384.92%|
|2018-Q1||$20,009 M||-0.92%||$4,367 M21.8%||-140.76%|
|2018-Q2||$20,830 M||4.10%||$3,954 M19.0%||-9.46%|
|2018-Q3||$20,348 M||-2.31%||$3,934 M19.3%||-0.51%|
|2018-Q4||$20,394 M||0.23%||$3,042 M14.9%||-22.67%|
|2019-Q1||$20,021 M||-1.83%||$3,749 M18.7%||23.24%|
Johnson & Johnson ownershipWhen you are planning to invest in shares of a company, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Johnson & Johnson, 0.07% of all outstanding shares are owned by its staff.
In case of Johnson & Johnson stock, 69.23% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for JNJ stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$354.9 B||$151.7 B||$109.8 B||$108.7 B||$150.2 B|
|Total shares||2,630.0 M||1,770.0 M||2,490.0 M||960.1 M||1,340.0 M|
|Float shares||2,630.0 M||1,760.0 M||2,450.0 M||842.1 M||1,340.0 M|
|- Institutional holdings (%)||69.2%||76.5%||11.0%||81.5%||84.2%|
|- Insider holdings (%)||0.1%||0.7%||0.0%||0.1%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, November 15th, 2019|
|Day range||$130.78 - $134.97|
|Average true range||$1.96|
|50d mov avg||$130.79|
|100d mov avg||$131.29|
|200d mov avg||$133.55|
Johnson & Johnson performanceTo better understand Johnson & Johnson performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Johnson & Johnson performance to , GlaxoSmithKline, Eli Lilly and, Medtronic, Merck, Novartis, Pfizer, and Stryker:
|LLYEli Lilly and||3.00%||-1.32%||1.68%|
Johnson & Johnson competitorsWe selected a few stocks to conform a list of Johnson & Johnson competitors to check if you are interested in investing in JNJ:
- GlaxoSmithKline (GSK)
- Eli Lilly and (LLY)
- Medtronic (MDT)
- Merck (MRK)
- Novartis (NVS)
- Pfizer (PFE)
- Stryker (SYK)
Latest JNJ stock news
- InvestorPlaceWhy Johnson & Johnson Stock Isn’t a Buy… YetJuly 29, 2019
- Seeking AlphaJohnson & Johnson's Stock May Be Too Cheap In A Low Interest Rate WorldJuly 24, 2019
- InvestorPlaceIs Johnson & Johnson Stock Losing Its Shine?July 24, 2019
- InvestorPlaceJohnson & Johnson Could Turn Around After its Strong EarningsJuly 24, 2019
- InvestorPlaceJohnson & Johnson Earnings: JNJ Stock Dips Despite Q2 Beat, Raised GuidanceJuly 16, 2019